Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Naim Alkhouri, M.D., currently serves as a Staff Physician with Digestive Disease Institute and Cleveland Clinic’s Children’s Hospital.
Dr. Alkhouri is board certified in internal medicine and pediatrics. He completed his medical degree at the University of Damascus, Damascus, Syria. His post-graduate training includes a one-year internal medicine and pediatric internship followed by a three-year internal medicine and pediatric residency at Albert Einstein Medical Center in Philadelphia; a three-year pediatric gastroenterology, hepatology and nutrition fellowship at Cleveland Clinic; and finally, an Adult Transplant Hepatology fellowship at the Digestive Disease Institute, Cleveland Clinic.
Dr. Alkhouri is a member of several professional organizations, including the American Association for the Study of Liver Disease; American Gastroenterology Association; American College of Gastroenterology; and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.
Among many research awards over the years, Dr. Alkhouri recently received the American College of Gastroenterology Junior Faculty Development Award to investigate volatile organic compounds in the breath of patients with liver disease. He also received the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Fellow Research Award for his prospective evaluation of the pediatric NAFLD fibrosis index and ELF markers in children with fatty liver disease.
Dr. Alkhouri is an established clinical and basic researcher and has published multiple research articles in peer-reviewed journals, textbook chapters, as well as having contributed abstracts and presentations at a number of professional association meetings.
Dr. Alkhouri’s specialty interests include nonalcoholic fatty liver disease, viral hepatitis, autoimmune liver disease, metabolic liver disease, end stage liver disease, liver transplantation, and alpha-1 antitrypsin deficiency.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 7/9/2015, Dr. Alkhouri has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.